New genomic research amends earlier triple negative breast cancer finding

Investigators tried to validate a previously reported molecular finding on triple negative breast cancer that many hoped would lead to targeted treatments for the aggressive disease. Instead, they discovered that the findings were limited to a single patient and could not be applied to further clinical work. This discovery amends the earlier work and underscores the importance of independent study validation and careful assay development.



from Today's Healthcare News -- ScienceDaily http://ift.tt/1FLDooF